Full-Time

Hemophilia Community Engagement Lead

Multiple Teams

Posted on 9/23/2025

Deadline 10/8/25
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$156.6k - $261k/yr

+ Bonus

No H1B Sponsorship

Washington, USA + 9 more

More locations: Oregon, USA | California, USA | Montana, USA | Nevada, USA | Arizona, USA | Arkansas, USA | Utah, USA | Hawaii, USA | Idaho, USA

Remote

Preferred location to live: California

Category
Growth & Marketing (2)
,
Requirements
  • B.S. or B.A. Degree is required
  • Minimum 7-10 years pharmaceutical industry or related experience -preferably in Rare Disease and/or working with patient advocacy groups / organizations
  • Account management experience; to include demonstrated experience partnering with external organizations to pull through key initiatives that align with internal business objectives
  • Experience demonstrating exceptional communication, listening, and platform trained speakers
  • Headquarters knowledge and experience and proven record working with cross functional HQ teams and business units
  • Demonstrated ability to work in a highly regulated environment and adhere to strict company compliance guidelines and procedures
  • Proven track record of collaborating broadly with a diverse range of customers, clients, and stakeholders
  • Experience in responsible business practices and compassionate communication both written and spoken
  • Strong strategic skills including effectiveness in identifying and addressing major strategic challenges (e.g. shifting market environment) and the ability to balance short-term needs with long-term vision.
  • Understands and navigates compliance guidelines aligned to working with MO&A (Medical) and ADM Teams (State Gov)
  • Requires leading without positional authority at all levels
  • Excellent communication skills, both written and verbal – bilingual a plus
  • Excellent presentation skills to address leadership and external audiences
  • Exceptional relationship building skills with a range of stakeholders (patients, EDs, caregivers)
  • Strong attention to detail, organizational and business skills
  • Ability to work in a team environment
  • Ability to travel at a minimum of 50%; scope of events is primarily on weekends and evenings
  • Valid US driver’s license and driving record in compliance with company standards. Any DUI/DWI or other impaired driving citation within the past 7 years will disqualify you from being hired.
Responsibilities
  • Define the strategy to increase patient engagement with the Patient Navigator and implement it with prioritized PAGs and with cross-functional partners, as appropriate.
  • Gathers and synthesizes market insights within their regions and leads priority assessments with PAG/CP Executive Directors to anticipate, identify and interpret trends that lead to the translation of trends into solutions/responses for patients.
  • Collaborate with Pfizer’s State and Government Affairs Team to support PAGs with state and local policy initiatives.
  • Understand and leverage the capabilities of local PAGs to develop programs and events that can connect patients & caregivers to Pfizer’s Hemophilia Patient Navigator (PN).
  • Manage budgets, sponsorships, events and collaborations with local PAGs that provide disease and brand education to help connect patients to Pfizer’s Hemophilia Patient Navigator.
  • Identify collaborative partnerships and regional initiatives where we could broaden our reach to the hemophilia community aligned to disease education, access to care and empowerment.
  • Conduct needs assessments with PAGs / CPs to identify areas of primary focus and to determine points of alignment with Pfizer goals and objectives.
  • Responsible for leading quarterly reviews to leadership, articulating our impact in supporting patients.
  • Help build a market analysis for a large territory to effectively partner with customers and address significant customer/ marketplace dynamics.
  • Identify key stakeholders, PAG/CP capabilities, and the local market as it relates to capacity building and the needs of the RD Community.
  • Builds rapport with key decision makers and is seen as a strategic resource.
  • Understands and strictly complies with all relevant regulations and policies. All activities are executed in close collaboration with legal and compliance to ensure that they are implemented in a thoughtful and compliant manner that meets Pfizer’s high standards of conduct.
  • Provide local insights to inform Hemophilia Brand Team on the development of educational materials for patient engagement and patient support resources that fill needs within the patient community.
  • Maintain awareness of the government landscape within the hemophilia communities on local, regional, and national levels.
  • Compliantly collaborate with Hemophilia Sales Managers (HSM), as needed, to ensure that the integrated patient offerings align with intended objectives in the context of local market dynamics.
  • Assist in effectively and compliantly communicating insights into the changing competitive landscape within Rare Disease and hemophilia to appropriate cross-functional colleagues.
  • Schedule and organize travel in a timely, thorough manner and order all required materials for local, regional, and national events.
  • Effectively maintain administrative responsibilities, i.e... expense report (Concur), budget tracker, activity tracker, Centris (initiating & closing a program), PN / Specialty Patient Solutions team calendar.
  • Actively collaborate with local cross-functional partners to share market insights, learnings from programs & events, and continue proactive engagement with patient organizations.
  • Regional partnerships across PAGs and CPs to bring the community together on larger issues that impact access to care.
Desired Qualifications
  • Significant experience in the Rare Disease marketplace, with an understanding of how to frame complex challenges to the organization with a solutions orientation
  • Forward looking and results oriented with effective planning, prioritization and organizational project skills
  • Track record of leading and managing complex projects to deliver improved outcomes
  • Demonstrates the ability to build strategic partnerships.
  • State and local policy initiative work
  • Manage and maintain budgets that align with brand strategy
  • Conducts integrated accounting meetings monthly to align with other internal business colleagues
  • Outstanding collaboration and networking abilities with PAGs / CPs
  • Knowledge of the Rare Disease community
  • Knowledge of Centris, Concur, Budget tracking, and an understanding of Sponsorship processes
  • Adherence to regulatory and compliance standards
  • Certain areas require bilingual- proficiency in speaking and reading

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer medicines grew 22% operationally in Q1 2026, led by Padcev up 39% and Lorbrena up 32%.
  • VYNDAMAX patent extended to 2031 secures 75% US prescription share in cardiology.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma use against J&J and BMS competitors.

What critics are saying

  • Eliquis patent expiry in 2026 triggers generic entry, eroding $17B peak cardiology sales.
  • Ibrance loses exclusivity in 2027, unleashing generics that destroy $5B breast cancer revenue.
  • Rigel deal forfeits Pfizer's Veppanu royalties, ceding 50-70% of breast cancer peak sales.

What makes Pfizer unique

  • Pfizer pioneered VEPPANU, FDA-approved first PROTAC therapy for ESR1-mutated breast cancer in May 2026.
  • Seagen acquisition doubled Pfizer's ADC trials across bladder, breast, lung, and colorectal cancers.
  • Flatiron Health collaboration since 2014 integrates real-world data for NSCLC and CRC development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE